Encouraging results from 2022 AACR maveropepimut-S, intermittent low-dose cyclophosphamide combined with pembrolizumab in advanced, metastatic bladder cancer

Introduction The 2022 American Association for Cancer Research Annual Meeting (AACR) will be held online from 4.
8-4.
13 local time
.

As one of the largest cancer research conferences in the world, AACR brings together oncology research and clinical progress from around the world
.

Safety, preliminary efficacy, and efficacy of the combination of maveropepimut-S (MVP-S), intermittent low-dose cyclophosphamide, and pembrolizumab in patients with advanced, metastatic bladder cancer The academic analysis data was announced at this conference, let's take a look
.

1 Background MVP-S is a novel immunotherapy drug that can induce CD8 T cells to specifically respond to the tumor antigen survivin, and eliminate survivn-expressing tumor cells through an immune response
.

Previous clinical studies have confirmed that MVP-S and intermittent low-dose cyclophosphamide (CPA) can produce confirmed clinical remission (partial and complete remission according to RECISTv1.
1 criteria) and induce stable, durable, Survivin-specific CD8 T cell responses
.

In addition, the combination regimen of MVP-S with pembrolizumab was well tolerated in both solid tumors and lymphomas
.

This phase II study was designed to investigate the safety and efficacy of this combination regimen in patients with advanced metastatic bladder cancer (regardless of whether the patients were previously treated with an immune checkpoint inhibitor)
.

Figure 1 Mechanism of action of MVP-S drugs 2 Results 17 subjects received the combination therapy of MVP-S, intermittent low-dose cyclophosphamide and pembrolizumab
.

The mean number of previous treatment lines was 3, and 13 (76.
4%) subjects had received anti-PD1/L1 therapy
.

Seven subjects had disease progression on or after anti-PD1/L1 as the last line of therapy prior to inclusion in this study
.

Figure 2 Patient demographics 5 of the 17 subjects responded, 3 achieved PR (unconfirmed) and 2 achieved CR (confirmed)
.

Three of the five responders (including two in CR) had prior disease progression on anti-PD1/L1 therapy
.

Long-term clinical benefit of the combination regimen has been observed in several subjects (one subject was thrown off treatment after 17 months), along with increased numbers of survivin-specific T cells in peripheral blood
.

Figure 3 Patient response The combination regimen was well tolerated, with most adverse events of grade 1 or 2
.

Figure 4 Treatment-Related Adverse Events 3 Conclusions Preliminary data suggest that MVP-S/CPA and pembrolizumab is a well-tolerated combination regimen that has shown promise in the treatment of patients with advanced or metastatic bladder cancer Encouraging clinical activity, even in patients previously treated with anti-PD-1/L1
.

The follow-up results of the study are worth looking forward to
.

Reference: Olivier Rixe, Vincent Castonguay, Henry Conter et al.
Safety, preliminary efficacy and pharmacodynamic (PD) analysis of maveropepimut-S, intermittent low-dose cyclophosphamide and pembrolizumab in patients with advanced, metastatic bladder cancer.
2022 AACR Meeting.
CT035 .
Edit: LR Reviewer: XY Execution: LR